Table 1. Studies evaluating the impact... | American Society of Hematology

Table 1.

Studies evaluating the impact of donor-recipient KIR-ligand mismatch in related or unrelated donor HSCT

Reference	Davies 2002²⁵	Giebel 2003²²	Bornhäuser 2004²³	Schaffer 2004⁷⁵	Hsu 2005⁷⁸	Beelen 2005⁸⁰	Verheyden 2005⁷⁹	Farag 2006⁷⁴	Chen 2006²⁴	Kröger 2006⁷³	Sun 2007²⁷	Miller 2007⁷⁶
No. of patients	175	130	118	190	178	374	65	1571	131	142	378	2062
Disease	CML, AML, ALL, others, (other leukemias, MDS, metabolic disease, immune deficiencies, SAA)	ALL, AML, MDS, CML, NHL, HL, MM	AML, CML, MDS	ALL, AML, CML, MDS, NHL, HL, MM	AML, ALL, CML, MDS	AML, CML, MDS	AML, CML, ALL	AML, MDS, CML	AML, CML, ALL, MDS, NHL, other	AML, MDS, CMML, ALL	ALL, AML, MDS, CML	AML, CML, MDS
Donor	URD	URD	URD	URD	HLA-matched sibling	Related or URD	HLA-matched sibling	URD	HLA-matched sibling	URD	HLA-matched sibling/ URD	URD
TCD (%)	37 in KIR-ligand compatible group; 29 in KIR-ligand incompatible group	ATG (100)	TCD (20) + ATG (100)	TCD (17) + ATG (100)	100	0	TCD (52)	20	No	ATG	No	—
KIR-ligand mismatched (GvH direction) (%)	35	15	13	12	63	13	68	9	63	70	16	—
Proportion of patients with aGVHD (grade 2-4) in KIR-ligand mismatched vs matched groups	NS	NS	NS	NS	NS	NS	NS	NS; aGVHD III to IV higher in KIR-ligand mismatch	NS	NS		NS; aGVHD III to IV higher in KIR-ligand mismatch (CML patients >1 year from diagnosis only)
Risk								HR, 1.64				RR, 1.58
95% CI								1.11–2.42				1.13-2.22
P								.001				.008
Relapse	NS	NS	Higher in KIR-ligand mismatch	NS	Lower in KIR-ligand mismatch (myeloid only)	Lower in KIR-ligand mismatch	NS	Higher in KIR-ligand mismatch	NS	NS	Higher in KIR-ligand mismatch	Lower in KIR-ligand mismatch (myeloid early disease only)
Risk					HR, 0.41	RR, 0.24		HR, 1.56			RR, 2.98	RR, 0.54
95% CI					0.18-0.97	0.08-0.69		0.88–2.75			1.17-7.59	0.30-0.95
P			.02		.04	< .008		.04			.02	.03
OS	Lower in KIR-ligand mismatch (myeloid only)	Higher in KIR-ligand mismatch	NS	Lower in KIR-ligand mismatch	Higher in KIR-ligand mismatch (myeloid only)	NS	NS	Lower in KIR-ligand mismatch	NS	Lower in KIR-ligand mismatch	NS	NS
Risk	13% vs 38% at 5 years	87% vs 48% at 4.5 years		HR, 2.13	HR, 0.53			HR, 1.94		HR, 2.015
95% CI	0%-26% vs 24%-52%			1.17-3.90	0.3-0.93			1.47-2.57
P	< .01	.006		.01	.026			< .001		.02

Reference	Davies 2002²⁵	Giebel 2003²²	Bornhäuser 2004²³	Schaffer 2004⁷⁵	Hsu 2005⁷⁸	Beelen 2005⁸⁰	Verheyden 2005⁷⁹	Farag 2006⁷⁴	Chen 2006²⁴	Kröger 2006⁷³	Sun 2007²⁷	Miller 2007⁷⁶
No. of patients	175	130	118	190	178	374	65	1571	131	142	378	2062
Disease	CML, AML, ALL, others, (other leukemias, MDS, metabolic disease, immune deficiencies, SAA)	ALL, AML, MDS, CML, NHL, HL, MM	AML, CML, MDS	ALL, AML, CML, MDS, NHL, HL, MM	AML, ALL, CML, MDS	AML, CML, MDS	AML, CML, ALL	AML, MDS, CML	AML, CML, ALL, MDS, NHL, other	AML, MDS, CMML, ALL	ALL, AML, MDS, CML	AML, CML, MDS
Donor	URD	URD	URD	URD	HLA-matched sibling	Related or URD	HLA-matched sibling	URD	HLA-matched sibling	URD	HLA-matched sibling/ URD	URD
TCD (%)	37 in KIR-ligand compatible group; 29 in KIR-ligand incompatible group	ATG (100)	TCD (20) + ATG (100)	TCD (17) + ATG (100)	100	0	TCD (52)	20	No	ATG	No	—
KIR-ligand mismatched (GvH direction) (%)	35	15	13	12	63	13	68	9	63	70	16	—
Proportion of patients with aGVHD (grade 2-4) in KIR-ligand mismatched vs matched groups	NS	NS	NS	NS	NS	NS	NS	NS; aGVHD III to IV higher in KIR-ligand mismatch	NS	NS		NS; aGVHD III to IV higher in KIR-ligand mismatch (CML patients >1 year from diagnosis only)
Risk								HR, 1.64				RR, 1.58
95% CI								1.11–2.42				1.13-2.22
P								.001				.008
Relapse	NS	NS	Higher in KIR-ligand mismatch	NS	Lower in KIR-ligand mismatch (myeloid only)	Lower in KIR-ligand mismatch	NS	Higher in KIR-ligand mismatch	NS	NS	Higher in KIR-ligand mismatch	Lower in KIR-ligand mismatch (myeloid early disease only)
Risk					HR, 0.41	RR, 0.24		HR, 1.56			RR, 2.98	RR, 0.54
95% CI					0.18-0.97	0.08-0.69		0.88–2.75			1.17-7.59	0.30-0.95
P			.02		.04	< .008		.04			.02	.03
OS	Lower in KIR-ligand mismatch (myeloid only)	Higher in KIR-ligand mismatch	NS	Lower in KIR-ligand mismatch	Higher in KIR-ligand mismatch (myeloid only)	NS	NS	Lower in KIR-ligand mismatch	NS	Lower in KIR-ligand mismatch	NS	NS
Risk	13% vs 38% at 5 years	87% vs 48% at 4.5 years		HR, 2.13	HR, 0.53			HR, 1.94		HR, 2.015
95% CI	0%-26% vs 24%-52%			1.17-3.90	0.3-0.93			1.47-2.57
P	< .01	.006		.01	.026			< .001		.02

aGVHD, acute graft-versus-host disease; ATG, anti-thymocyte globulin; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; HL, Hodgkin lymphoma; HR, hazard ratio; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NS, nonsignificant; RR, relative risk; SAA, severe aplastic anemia; TCD, T-cell depletion; URD, unrelated donor.

View Large

This Feature Is Available To Subscribers Only